Redhill Biophrma ADR (RDHL)

$1.48 -0.15 (-9.20%)
Market Cap 3.93M
Revenue (ttm) 8.04M
Net Income (ttm) -8.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -102.86%
Debt to Equity Ratio 0.00
Volume 141,151
Avg Vol 564,610
Day's Range N/A - N/A
Shares Out 2.30M
Stochastic %K 1%
Beta 4.22
Analysts Strong Buy
Price Target $40.00

Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear ra...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 541 3131
Fax: 972 3 541 3144
Address:
21 Ha’arba’a Street, Tel Aviv, Israel
Patrick2343
Patrick2343 Jul. 29 at 5:36 PM
$RDHL and yet they are diluting like crazy
1 · Reply
Patrick2343
Patrick2343 Jul. 29 at 5:35 PM
$RDHL they are diluting this so fast it will be .50 cents by next week. Does the company even exist I am really starting to wonder. Biggest scam I have ever owned
1 · Reply
therealchorris
therealchorris Jul. 29 at 4:45 PM
$RDHL Dead 💀
0 · Reply
Patrick2343
Patrick2343 Jul. 29 at 3:50 PM
$RDHL dilute dilute dilute to 0 its all they know
0 · Reply
3PintBrain
3PintBrain Jul. 28 at 8:21 PM
$RDHL Target Price: 19,000.00 ?
1 · Reply
Patrick2343
Patrick2343 Jul. 28 at 7:26 PM
$RDHL at what point will there be nothing left to dilute. I have never ever owned a stock in my life that dilutes more and accomplishes nothing
0 · Reply
3PintBrain
3PintBrain Jul. 28 at 6:50 PM
$RDHL Someone wanna do the math on how many OS this co had 2 years ago before 2 R/S? Currently sitting around 13 Billion. lol
0 · Reply
3PintBrain
3PintBrain Jul. 28 at 6:42 PM
$RDHL I can see it now, likely a drop overnight and then a green day coming back to today's low. Garbage!
0 · Reply
therealchorris
therealchorris Jul. 28 at 6:27 PM
$RDHL Wow, freefall. Talking about non-dilutive funding while diluting. Amazing.
2 · Reply
Patrick2343
Patrick2343 Jul. 28 at 3:30 PM
$RDHL dilute dilute dilute and rs coming soon these guys are just con artists
1 · Reply
Latest News on RDHL
RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

Jul 21, 2025, 9:00 AM EDT - 8 days ago

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Jul 1, 2025, 12:00 PM EDT - 4 weeks ago

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

May 13, 2025, 7:00 AM EDT - 2 months ago

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

May 2, 2025, 7:00 AM EDT - 3 months ago

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

Apr 28, 2025, 7:03 AM EDT - 3 months ago

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Apr 17, 2025, 4:01 PM EDT - 3 months ago

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

Apr 16, 2025, 7:00 AM EDT - 3 months ago

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Apr 10, 2025, 7:48 AM EDT - 3 months ago

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Mar 18, 2025, 7:00 AM EDT - 4 months ago

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

Mar 12, 2025, 7:00 AM EDT - 4 months ago

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

Feb 27, 2025, 7:00 AM EST - 5 months ago

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

Feb 25, 2025, 7:00 AM EST - 5 months ago

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

Feb 4, 2025, 7:00 AM EST - 6 months ago

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Jan 21, 2025, 7:00 AM EST - 6 months ago

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Dec 10, 2024, 7:00 AM EST - 8 months ago

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

Dec 2, 2024, 7:00 AM EST - 8 months ago

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

Oct 28, 2024, 7:00 AM EDT - 9 months ago

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

Oct 22, 2024, 7:00 AM EDT - 10 months ago

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

Oct 14, 2024, 7:00 AM EDT - 10 months ago

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

Oct 1, 2024, 7:00 AM EDT - 10 months ago

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

Sep 30, 2024, 7:00 AM EDT - 10 months ago

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

Sep 9, 2024, 7:00 AM EDT - 11 months ago

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 5, 2024, 7:00 AM EDT - 11 months ago

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

Sep 3, 2024, 7:00 AM EDT - 11 months ago

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

RedHill Biopharma Announces First Half 2024 Business Highlights

Aug 29, 2024, 7:00 AM EDT - 11 months ago

RedHill Biopharma Announces First Half 2024 Business Highlights

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Aug 26, 2024, 7:00 AM EDT - 1 year ago

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Talicia® Launched in the United Arab Emirates

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Talicia® Launched in the United Arab Emirates

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

Aug 19, 2024, 8:56 AM EDT - 1 year ago

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

Aug 19, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Aug 16, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

Aug 1, 2024, 7:00 AM EDT - 1 year ago

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

Jul 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

RedHill Biopharma Terminates License Agreement for Aemcolo®

Jul 9, 2024, 8:00 AM EDT - 1 year ago

RedHill Biopharma Terminates License Agreement for Aemcolo®

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

Jun 3, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

May 6, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

Apr 24, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

Apr 8, 2024, 9:23 AM EDT - 1 year ago

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

Apr 2, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

Mar 11, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Mar 5, 2024, 7:00 AM EST - 1 year ago

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

GILD

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

Feb 20, 2024, 7:00 AM EST - 1 year ago

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

AMGN GILD

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

Jan 26, 2024, 12:46 PM EST - 1 year ago

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

RedHill Biopharma Announces $8 Million Registered Direct Offering

Jan 25, 2024, 9:05 AM EST - 1 year ago

RedHill Biopharma Announces $8 Million Registered Direct Offering

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

Jan 25, 2024, 6:00 AM EST - 1 year ago

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

RedHill Biopharma shares jump as Ebola treatment shows promise

Dec 20, 2023, 9:13 AM EST - 1 year ago

RedHill Biopharma shares jump as Ebola treatment shows promise

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

Dec 20, 2023, 8:45 AM EST - 1 year ago

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

Dec 4, 2023, 7:00 AM EST - 1 year ago

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.

Nov 30, 2023, 9:33 AM EST - 1 year ago

These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.

AAPL ABBV AMC AMZN CRM DIS GME

RedHill Biopharma (RDHL) gained 216% after FDA approvals: Buy Now!

Nov 28, 2023, 11:54 AM EST - 1 year ago

RedHill Biopharma (RDHL) gained 216% after FDA approvals: Buy Now!

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

Nov 27, 2023, 7:00 AM EST - 1 year ago

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

Patrick2343
Patrick2343 Jul. 29 at 5:36 PM
$RDHL and yet they are diluting like crazy
1 · Reply
Patrick2343
Patrick2343 Jul. 29 at 5:35 PM
$RDHL they are diluting this so fast it will be .50 cents by next week. Does the company even exist I am really starting to wonder. Biggest scam I have ever owned
1 · Reply
therealchorris
therealchorris Jul. 29 at 4:45 PM
$RDHL Dead 💀
0 · Reply
Patrick2343
Patrick2343 Jul. 29 at 3:50 PM
$RDHL dilute dilute dilute to 0 its all they know
0 · Reply
3PintBrain
3PintBrain Jul. 28 at 8:21 PM
$RDHL Target Price: 19,000.00 ?
1 · Reply
Patrick2343
Patrick2343 Jul. 28 at 7:26 PM
$RDHL at what point will there be nothing left to dilute. I have never ever owned a stock in my life that dilutes more and accomplishes nothing
0 · Reply
3PintBrain
3PintBrain Jul. 28 at 6:50 PM
$RDHL Someone wanna do the math on how many OS this co had 2 years ago before 2 R/S? Currently sitting around 13 Billion. lol
0 · Reply
3PintBrain
3PintBrain Jul. 28 at 6:42 PM
$RDHL I can see it now, likely a drop overnight and then a green day coming back to today's low. Garbage!
0 · Reply
therealchorris
therealchorris Jul. 28 at 6:27 PM
$RDHL Wow, freefall. Talking about non-dilutive funding while diluting. Amazing.
2 · Reply
Patrick2343
Patrick2343 Jul. 28 at 3:30 PM
$RDHL dilute dilute dilute and rs coming soon these guys are just con artists
1 · Reply
Patrick2343
Patrick2343 Jul. 25 at 8:06 PM
$RDHL With the way they are diluting I would not be shocked to see this go under a buck in the next few weeks
1 · Reply
Patrick2343
Patrick2343 Jul. 25 at 8:04 PM
$RDHL That is because they pumped so they could dilute. That is what they do over and over and over again. The company is a total scam
1 · Reply
therealchorris
therealchorris Jul. 25 at 7:53 PM
$RDHL Lost almost half its value in one week and fell to 52 weeks low.
0 · Reply
3PintBrain
3PintBrain Jul. 25 at 5:46 PM
$RDHL So google has about 5 bill outstanding shares, this has, somehow, 12 billion. How is that even possible? This thing is dilution machine.
0 · Reply
Stockking24
Stockking24 Jul. 24 at 7:17 PM
$RDHL This one looks dead until they decide to pump it again. The last run didn’t even come close to the previous high. All I’m seeing now is dilution and nonsense. I’ve lost too much on this one before trusting the fundamentals — won’t make that mistake again. I’ll keep watching, but if I were holding, I’d just wait it out and hope for another pump. If not… well, it might just end up being a tax loss harvest.
2 · Reply
3PintBrain
3PintBrain Jul. 24 at 6:04 PM
$RDHL Break $2 might see a mini squeeze on daily!
0 · Reply
3PintBrain
3PintBrain Jul. 24 at 4:54 PM
$RDHL Down 99.99% all time. Sounds legit!
0 · Reply
Samuelstark
Samuelstark Jul. 24 at 3:52 PM
$RDHL Super low float. Just need some buying pressure. Maybe.🤔
1 · Reply
Patrick2343
Patrick2343 Jul. 23 at 5:19 PM
$RDHL maybe one day something will but until then its pump and dump and dilute like crazy. They love to dilute
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 23 at 12:52 AM
Money Wednesday Part 5 $PSTV $TLRY $OPAD $RDHL $IXHL Let's Do Well Tomorrow
1 · Reply
3PintBrain
3PintBrain Jul. 22 at 5:36 PM
$RDHL I know it's yesterday's news but just repeating the non dilutive aspect for anyone who missed that! RedHill Biopharma Ltd. Advances RHB-204 with Positive FDA Feedback and Ongoing Non-Dilutive Funding Efforts
0 · Reply
MadMaverick
MadMaverick Jul. 22 at 3:12 PM
$RNXT - Late July Phase III data targeting pancreatic cancer, echoing recent biotech surges: 🔹 $INAB +150% on gene therapy news 🔹 $TCRT +80% after CAR-T trial update 🔹 $RDHL +58% after FDA feedback for trial 🔹 $PMN +145% after Fast Track Designation news Looking for a technical breakout from descending channel attracting swing traders https://chartingdaily.com/RNXT-stock Communicated Disclaimer - Do your own research too.
2 · Reply